Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Markers of glucose metabolism associated with colorectal adenomas

July's issue of Gastroenterology studies the association between markers of glucose metabolism and metabolic syndrome and the presence of colorectal adenomas.

News image

Diabetes is a risk factor for colorectal cancer.

Dr Juhee Cho and colleagues from South Korea studied the association between markers of glucose metabolism and metabolic syndrome and the presence of colorectal adenomas in a large number of asymptomatic men and women attending a health screening program in South Korea.

The research team also investigated whether these associations depend on adenoma location.

In a cross-sectional study, the team measured fasting levels of glucose, insulin, hemoglobin A1c, and C-peptide and calculated homeostatic model assessment (HOMA) values for 19,361 asymptomatic South Korean subjects who underwent colonoscopy examinations from 2006 to 2009.

Participants completed a standardized self-administered health questionnaire and a validated semiquantitative food frequency questionnaire.
The prevalence ratio for any adenoma was 1.08 for fasting glucose 
Gastroenterology

Blood samples were collected on the day of the colonoscopy, and fasting blood samples were also collected.

Robust Poisson regression was used to model the associations of glucose markers with the prevalence of any adenoma.

Using detailed multivariable-adjusted dose-response models, the prevalence ratios for any adenoma, comparing the 90th with the 10th percentile, were 1.08 for fasting glucose, 1.07 for insulin, 1.09 for HOMA, 1.09 for hemoglobin A1c, and 1.14 for C-peptide.

The research team noted that the corresponding ratios for nonadvanced adenomas were 1.11, 1.10, 1.15, 1.14, and 1.20, respectively.

The team found that the corresponding ratios for advanced adenomas were 1.32, 1.23, 1.30, 1.13, and 1.67, respectively.

The team noted that metabolic syndrome was associated with the prevalence of any adenoma, nonadvanced adenoma, and advanced adenoma.

Associations were similar for adenomas located in the distal versus proximal colon.

Dr Cho's team concludes, "Increasing levels of glucose, HOMA values, levels of hemoglobin A1c and C-peptide, and metabolic syndrome are significantly associated with the prevalence of adenomas."

"Adenomas should be added to the list of consequences of altered glucose metabolism."

Gastroenterol 2014: 147(1): 78–87.e3
26 June 2014

Go to top of page Email this page Email this page to a colleague

 27 February 2015

Advanced search
 27 February 2015 
Obesity and weight-loss therapy
 27 February 2015 
MRE performance in staging liver fibrosis
 27 February 2015 
Bleeding in diverticulosis
 26 February 2015 
Familial colorectal cancer risk and primary cancer
 26 February 2015 
Questionnaires for GERD
 26 February 2015 
Herbal products and the liver
 25 February 2015 
Exercise and NAFLD
 25 February 2015 
IBD in Korea
 25 February 2015 
Immunosuppressive therapy and T. whipplei
 24 February 2015 
Clinical trials in pediatric IBD
 24 February 2015 
Reducing health care costs in IBD
 24 February 2015 
GI bleeding after anticoagulation interruption
 23 February 2015 
Visceral abdominal obesity and IBS
 23 February 2015 
Crohn's outcomes with infliximab
 23 February 2015 
Intestinal microbiota and celiac disease
 20 February 2015 
H. pylori eradication
 20 February 2015 
Antiviral treatment and Hep C outcomes
 20 February 2015 
C. diff testing in IBD
 19 February 2015 
Intestinal microbiota in IBS
 19 February 2015 
Peptic ulcer bleeding mortality in liver disease
 19 February 2015 
Fecal microbial transplant in active Crohn's disease
 18 February 2015 
Genetic testing and GI cancers
 18 February 2015 
Placebo analgesia in functional abdominal pain
 18 February 2015 
Successful Hep C virus therapy
 17 February 2015 
Quality measures and colonoscopist selection
 17 February 2015 
Global incidence of esophageal cancer
 17 February 2015 
Anti-viral treatment and survival in Hep C
 16 February 2015 
Saliva for the diagnosis of GERD
 16 February 2015 
H pylori eradication therapy
 16 February 2015 
Medical marijuana for digestive disorders
 13 February 2015 
Beta-blockers in cirrhosis
 13 February 2015 
Liver disease and peptic ulcer bleeding
 13 February 2015 
Prevalence of microscopic colitis
 12 February 2015 
Liver disease in chronic Hep C
 12 February 2015 
Patient-reported outcomes in Hep C
 12 February 2015 
Patients’ colonoscopist selection
 11 February 2015 
NAFLD and CVD
 11 February 2015 
Guidelines for the diagnosis of hepatocellular carcinoma
 11 February 2015 
Hepatic decompensation in Hep C cirrhosis
 10 February 2015 
Percutaneous endoscopic gastrostomy
 10 February 2015 
Factors that influence hepatic steatosis
 10 February 2015 
Gene variants and Crohn's susceptibility
 09 February 2015 
Factors that influence gallstone surgery
 09 February 2015 
Factors associated with increased mortality in cirrhosis
 09 February 2015 
Use of immunomodulators in IBD
 06 February 2015 
Colorectal cancer risk in IBD
 06 February 2015 
H. pylori and peptic ulcer bleeding
 06 February 2015 
IBS and somatization
 05 February 2015 
GERD, dyspepsia and IBS symptoms
 05 February 2015 
Quality of life in Crohn's after antitumor necrosis factor agents
 05 February 2015 
Thalidomide and refractory Crohn's
 04 February 2015 
Telemedicine in IBD
 04 February 2015 
Infliximab and muscle wasting in Crohn's
 04 February 2015 
Resistance mutations in chronic Hep B
 03 February 2015 
Testosterone in advanced liver disease
 03 February 2015 
Mortality in peptic ulcer bleeding
 03 February 2015 
Colonoscopic remission of ulcerative colitis
 02 February 2015 
Colonoscopy and colon cancer risk in IBD
 02 February 2015 
Sirolimus in Hep C virus infected liver graft recipients
 02 February 2015 
Treatment of C. diff in adults

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us